AR040121A1 - A COMBINATION OF NMDA ANTAGONIST AND INHIBITORS OF ACETILCOLINE ESTERASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE - Google Patents

A COMBINATION OF NMDA ANTAGONIST AND INHIBITORS OF ACETILCOLINE ESTERASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Info

Publication number
AR040121A1
AR040121A1 ARP030101849A ARP030101849A AR040121A1 AR 040121 A1 AR040121 A1 AR 040121A1 AR P030101849 A ARP030101849 A AR P030101849A AR P030101849 A ARP030101849 A AR P030101849A AR 040121 A1 AR040121 A1 AR 040121A1
Authority
AR
Argentina
Prior art keywords
inhibitors
acetilcoline
esterase
alzheimer
disease
Prior art date
Application number
ARP030101849A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28051666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040121(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR040121A1 publication Critical patent/AR040121A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica que comprende: (a) una cantidad efectiva de uno o más inhibidores de la acetilcolinesterasa o una sal farmacéuticamente efectiva de los mismos y (b) una cantidad efectiva de uno o más antagonistas de NMDA. Reivindicación 2: La composición de acuerdo con la reivindicación 1, en la cual el componente (a) es seleccionado entre el grupo que consiste en Tacrina,. Donepezil, Rivastigmina y Galantamina o mezclas de los mismos. Reivindicación 3: La composición de acuerdo con la reivindicación 2, en la cual el componente (a) es Donepezil. Reivindicación 4: La composición de acuerdo con la reivindicación 1; en el cual el componente (b) es Memantina.A pharmaceutical composition comprising: (a) an effective amount of one or more acetylcholinesterase inhibitors or a pharmaceutically effective salt thereof and (b) an effective amount of one or more NMDA antagonists. Claim 2: The composition according to claim 1, wherein the component (a) is selected from the group consisting of Tacrine. Donepezil, Rivastigmine and Galantamine or mixtures thereof. Claim 3: The composition according to claim 2, wherein the component (a) is Donepezil. Claim 4: The composition according to claim 1; in which component (b) is Memantine.

ARP030101849A 2002-05-31 2003-05-27 A COMBINATION OF NMDA ANTAGONIST AND INHIBITORS OF ACETILCOLINE ESTERASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AR040121A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200844 2002-05-31

Publications (1)

Publication Number Publication Date
AR040121A1 true AR040121A1 (en) 2005-03-16

Family

ID=28051666

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101849A AR040121A1 (en) 2002-05-31 2003-05-27 A COMBINATION OF NMDA ANTAGONIST AND INHIBITORS OF ACETILCOLINE ESTERASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Country Status (9)

Country Link
KR (1) KR101016927B1 (en)
CN (1) CN1655793A (en)
AR (1) AR040121A1 (en)
CA (1) CA2426492C (en)
EA (1) EA007632B1 (en)
IS (1) IS7558A (en)
PE (1) PE20040623A1 (en)
UA (1) UA82480C2 (en)
ZA (1) ZA200409147B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107653U (en) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" COMPOSITION OF MEDICINAL PRODUCTS FOR TREATMENT AND PREVENTION OF BEHAVIORAL, MENTAL, AND COGNITIVE DISORDERS
CN118290279A (en) * 2014-05-29 2024-07-05 广州喜鹊医药有限公司 Salts of amantadine nitrate compounds with neuroprotective effect
WO2018062941A1 (en) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 Pharmaceutical composition for preventing or treating dementia and cognitive dysfunction, containing donepezil or pharmaceutically acceptable salt thereof and memantine or pharmaceutically acceptable salt thereof, and preparation method therefor
KR20210072569A (en) 2019-12-09 2021-06-17 주식회사 종근당 Complex formulation comprising donepezil and memantine

Also Published As

Publication number Publication date
CA2426492A1 (en) 2003-09-16
CN1655793A (en) 2005-08-17
ZA200409147B (en) 2006-06-28
UA82480C2 (en) 2008-04-25
PE20040623A1 (en) 2004-09-11
KR101016927B1 (en) 2011-02-28
EA007632B1 (en) 2006-12-29
KR20050024296A (en) 2005-03-10
EA200401617A1 (en) 2005-06-30
IS7558A (en) 2004-11-26
CA2426492C (en) 2006-10-03

Similar Documents

Publication Publication Date Title
LU92853I2 (en) A COMBINATION OF RILPIVIRINE OR AN EQUIVALENT THERAPEUTIC FORM THEREFROM AS PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE RILPIVIRINE HYDROCHLORIDE SALT AND THE EMTRICITABINE
ATE414519T1 (en) COMBINATION OF AN NMDA ANTAGONIST AND ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ECSP066313A (en) DERIVATIVES OF PIRIDAZINE AND ITS USE AS THERAPEUTIC AGENTS
ECSP066315A (en) DERIVATIVES OF PIRIDAZINE AND ITS USE AS THERAPEUTIC AGENTS
ES2193391T3 (en) MUSCARINIC ANTAGONISTS.
BG66085B1 (en) Phenylalanine derivatives
ECSP066312A (en) PIRIDILO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
ATE269846T1 (en) N-SUBSTITUTED AMINOTETRALINES AS NEUROPEPTIDE Y Y5 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF OBESITY AND OTHER DISEASES
CO5570667A2 (en) SUBSTITUTED SUBSTITUTE SUBSTITUTED SUBSTITUTE COMPOUNDS WITH HETEROARILO FOR THE TREATMENT OF DISEASES
CO5630034A2 (en) PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS
DE60029799D1 (en) COMPOUNDS, PROCESSES AND PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CELL DAMAGE SUCH AS, FOR EXAMPLE, DAMAGE TO NERVE OR CANDLE TISSUE
UY26839A1 (en) PRODUCTS BY DERIVATIVES OF LA 4 - FENIL - PIRIDINA
AR034362A1 (en) ANALGESIC PROLONGED RELEASE COMPOUNDS
AR021844A1 (en) ARIL-SUBSTITUTED PROPANOLAMINE DERIVATIVES, PROCEDURES FOR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THEIR USE
AR037930A1 (en) DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS
EA200800880A1 (en) COMBINATION OF ROSIGLITAZONE AND DROPSEEN, INTENDED TO IMPROVE COGNITIVE FUNCTION
ATE355374T1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC DISEASES
ATE224884T1 (en) MUSCARINE ANTAGONISTS
DE69833971D1 (en) METHOD FOR TREATING ALZHEIMER'S DISEASE
CO5011095A1 (en) ACETILCOLINESTARASA INHIBITORS IN COMBINATION WITH MUSCARINIC AGENCIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NI200200095A (en) "PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN"
EA200200132A1 (en) SELECTIVE ANTAGONISTS OF THE RECEPTOR iGluRD FOR THE TREATMENT OF MIGRAINE
EA200200207A1 (en) APPLICATION OF CGRP ANTAGONISTS AND CGRP RELIEF INHIBITORS TO ELIMINATE TIDES IN THE PERIOD OF MENOPAUSE
CL2003002565A1 (en) COMPOUNDS DERIVED FROM 3H-QUINAZOLIN-4-ONA, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND USE IN THE TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MAO-B INHIBITORS, SUCH AS THE DISEASE OF ALZHEIMER AND DEMENCIER

Legal Events

Date Code Title Description
FB Suspension of granting procedure